+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effect of Nuvastatic on reducing cancer-related fatigue in adults with colon cancer who are undergoing first-line chemotherapy. This Phase III trial compares Nuvastatic to a placebo to determine if it can improve fatigue scores and assess its safety and tolerance in this patient group. The study is designed to provide supportive care alongside standard chemotherapy treatment. Participants will receive either Nuvastatic or placebo sachets, taken three times a day, for three cycles of 20 days each, totaling about 60 days of treatment. Alongside this, they will continue their usual chemotherapy regimen. Blood samples will be collected at screening and at the end of treatment to measure certain biomarkers, including CEA and CA-125. During the study, participants will complete diaries and fatigue assessments as scheduled by the protocol. Researchers will monitor changes in fatigue levels from screening up to 12 weeks and evaluate overall quality of life and functional improvements at the start and end of the study. The trial includes safety monitoring and aims to understand the treatments impact over a 12-week period.

Age: 18Years - 65YearsAll GendersPhase 3
6 locations